1. Home
  2. CSWC vs CAPR Comparison

CSWC vs CAPR Comparison

Compare CSWC & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capital Southwest Corporation

CSWC

Capital Southwest Corporation

HOLD

Current Price

$23.09

Market Cap

1.4B

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$24.05

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSWC
CAPR
Founded
1961
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Textiles
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CSWC
CAPR
Price
$23.09
$24.05
Analyst Decision
Buy
Strong Buy
Analyst Count
5
8
Target Price
$23.50
$41.38
AVG Volume (30 Days)
566.1K
1.3M
Earning Date
02-02-2026
11-10-2025
Dividend Yield
10.81%
N/A
EPS Growth
N/A
N/A
EPS
1.62
N/A
Revenue
$217,271,000.00
$11,130,509.00
Revenue This Year
$13.97
N/A
Revenue Next Year
$7.62
$16,329.74
P/E Ratio
$14.60
N/A
Revenue Growth
11.39
N/A
52 Week Low
$17.46
$4.30
52 Week High
$23.86
$40.37

Technical Indicators

Market Signals
Indicator
CSWC
CAPR
Relative Strength Index (RSI) 59.25 49.28
Support Level $22.85 $23.53
Resistance Level $23.84 $25.44
Average True Range (ATR) 0.44 1.73
MACD 0.07 -0.95
Stochastic Oscillator 61.08 12.97

Price Performance

Historical Comparison
CSWC
CAPR

About CSWC Capital Southwest Corporation

Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: